Total Revenues for Q2 Up 25%
Continue ReadingTag: akers-biosciences
Akers Biosciences Announces Board Changes
Experienced directors with medical device and financial backgrounds to steer the Company through next phase of…
Continue ReadingAkers Biosciences Announces Second Quarter Trading Update
Second Quarter Revenues Up 25% over Q2 2016
Continue ReadingAkers Biosciences Announces a $2 Million Private Placement
THOROFARE, NJ -- (Marketwired) -- 03/30/17 -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company"…
Continue ReadingAkers Biosciences Reports Preliminary Unaudited Earnings Highlights for Fiscal Year 2016
Sales of Flagship Rapid HIT Test +85% over 2015
Continue ReadingAkers Biosciences Announces Closing of Public Offering
THOROFARE, NJ -- (Marketwired) -- 01/13/17 -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company"…
Continue ReadingAkers Biosciences Announces Pricing of Public Offering of 1,667,000 Shares and 833,500 Warrants
THOROFARE, NJ -- (Marketwired) -- 01/09/17 -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company"…
Continue ReadingAkers Biosciences Signs 3-year Agreement with GNYHA Services for Heparin PF4 Rapid Test
THOROFARE, NJ -- (Marketwired) -- 12/22/16 -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company"…
Continue Reading